Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
WSJ·2025-10-15 13:17Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart. ...
WSJ·2025-10-15 13:17
WSJ·2025-10-15 13:17